Concord Medical Reports Financial Results for the First Half of 2021

BEIJING,Dec. 10,2021 -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM),a healthcare provider specializing in cancer care,research,and prevention by operating a network of medically advanced comprehensive cancer hospitals and standalone radiotherapy and diagnostic imaging centers in China,today announced its unaudited consolidated financial results for the six months ended June 30,2021[1].

2021 First Half Highlights

Total net revenues were RMB192.9 million ($29.9 million) in the first half of 2021,representing a 132.4% increase from total net revenues of RMB83.0 million in the same period last year. Total net revenues included the net revenues from the network business of RMB128.7 million ($20.0 million) and the net revenues from the hospital business of RMB64.2 million ($9.9 million).

Gross profit was RMB2.4 million ($0.4 million) in the first half of 2021,compared to the gross loss of RMB3.5 million in the first half of 2020. The gross profit margin was 1.23% for the first half of 2021,compared to the gross loss margin of 4.2% for the same period last year.

Net loss attributable to ordinary shareholders in the first half of 2021 was RMB90.3 million ($14.0 million),compared to RMB128.8 million in the same period last year.

Basic and diluted loss per share for Class A and Class B ordinary shares[2] in the first half of 2021 were both RMB2.53 ($0.39),compared to RMB2.23,respectively,in the same period last year.

Non-GAAP net loss in the first half of 2021 was RMB163.0 million ($25.3 million),compared to non-GAAP net loss of RMB155.0 million in the same period last year. Non-GAAP basic and diluted loss per share for Class A and Class B ordinary shares in the first half of 2021 were both RMB2.46 ($0.38),compared to RMB2.15 in the same period last year.

Adjusted EBITDA[3] (non-GAAP) was negative RMB127.7 million ($19.8 million) in the first half of 2021,compared to negative RMB113.1 million in the same period last year.

Dr. Jianyu Yang,Chairman and Chief Executive Officer of Concord Medical,commented,"Our performance in the first half of 2021 is highlighted by very strong revenue growth across regions and business sections. These results represent a remarkable recovery from the impact of the pandemic on our business,demonstrating the resilience of our people,as well as their commitment to each other and our clients. We believe that the opening of our new hospital will continuously shift our income structure from network business to hospital business with higher income potential."

"The Company's Guangzhou Concord Cancer Center (the "Guangzhou Hospital") was officially opened in June 2021. We believe that this will expand the Company's income from hospital business."

"The Company also officially opened an internet hospital in May 2021. The internet hospital aims to provide a series of cancer care services,ranging from cancer prevention to post-treatment recovery,on the Company's online platforms. We believe that the internet hospital will expand the influence of the Company's brand among the prime target groups of patients."

"We have cultivated our Cloud System Solutions business for our network business and recently-established internet hospital. Besides,the preparation of the proton therapy system at the Guangzhou Hospital is nearly competed,which is expected to be the only proton therapy system in the Southern China in the next few years. With the gradual operation of the proton center to the mature stage,we believe that the Company's revenue can be improved in the next few years."

2021 First Half Financial Results

Network Business

Net revenues from the network business were RMB128.7 million ($20.0 million),representing a 241.4% increase from net revenues of RMB37.7 million in the first half of 2020,primarily attributable to the Company's development of Cloud System Solutions of medical devices for its existing medical equipment and consumable sales services. With three centers closed in the first half of 2021,the Company operated a network of 24 centers in 18 cities in China as of June 30,2021.

Cost of revenues of the network business was RMB95.7 million ($14.8 million),representing a 555.5% increase from RMB14.6 million in the first half of 2020,primarily attributable to the Company's business expansion on consumable sales services.

Gross profit from the network business was RMB33.0 million ($5.1 million),representing a 42.9% increase from RMB23.1 million in the first half of 2020. The gross profit margin of the network business for the first half of 2021 was 25.6%,compared to the gross profit margin of 61.3% for the same period last year.

Selling expenses of the network business were RMB8.3 million ($1.3 million),representing a 57.2% decrease from RMB19.4 million in the first half of 2020. Selling expenses as a percentage of net revenues from the network business was 6.5% in the first half of 2021,compared to 51.5% in the first half of 2020. The decrease in selling expenses of the network business was mainly due to the decrease in staff cost and advertisement and promotion expenses.

General and administrative expenses of the network business were RMB72.3 million ($11.2 million),representing a 27.1% increase from RMB56.9 million in the first half of 2020. General and administrative expenses as a percentage of net revenues from the network business were 56.2% in the first half of 2021,compared to 150.9% in the same period last year.

Comparing to RMB3.9 million in the same period last year,capital expenditures decreased to RMB103.8 million ($16.1 million) in the first half of 2021,primarily for procuring equipment for network centers.

Accounts receivable were RMB73.7 million ($11.4 million) as of June 30,2021,compared to RMB61.9 million as of December 31,2020. The average period of sales outstanding for accounts receivable (also known as "Days Sales Outstanding") was 219 days in the first half of 2021.

During the first half of 2021,the Company handled 4,230 patient treatment cases and 31,204 patient diagnostic cases,representing a 10.2% increase and a 22.9% decrease from the same period last year,respectively. The decreases in diagnostic and overall cases were mainly due to the influence of the COVID-19 pandemic.

Hospital Business

Net revenues from the hospital business were RMB64.2 million ($9.9 million) in the first half of 2021,representing a 41.7% increase from net revenues of RMB45.3 million in the first half of 2020,mainly because the Company's operation of self-owned hospitals has gradually recovered from the adverse impact of theCOVID-19pandemic.

Cost of revenues of the hospital business in the first half of 2021 was RMB94.9 million ($14.7 million),representing a 32.2% increase from cost of revenues of RMB71.8 million in the first half of 2020,mainly because the labor cost increased for the preparation of the opening of Guangzhou Hospital,which has been in operation since June 2021.

Gross loss from the hospital business was RMB30.7 million ($4.8 million) in the first half of 2021,compared to RMB26.5 million in the same period last year. The gross loss margin of the hospital business for the first half of 2021 was 47.8%,compared to the gross loss margin of 58.5% for the same period last year.

Selling expenses of the hospital business were RMB5.4 million ($0.8 million) in the first half of 2021,representing an 100.0% increase from selling expenses of RMB2.7 million in the first half of 2020. Selling expenses as a percentage of net revenues from the hospital business was 8.3% in the first half of 2021,compared to 6.0% in the first half of 2020.

General and administrative expenses of the hospital business were RMB101.7 million ($15.7 million) in the first half of 2021,of which employee benefit expenses were RMB73.2 million ($11.3 million). In the same period of last year,general and administrative expenses of the hospital business were RMB77.5 million. The increase was mainly due to the increase in salary and rental fees for hospitals. General and administrative expenses as a percentage of net revenues from the hospital business was 158.5% in the first half of 2021,compared to 171.1% in the first half of 2020.

Comparing to RMB364.9 million in the first half of 2020,capital expenditures of the hospital were RMB310.6 million ($48.1 million) in the first half of 2021. The decrease was mainly related to the decrease in construction fees and medical equipment payment.

As of June 30,accounts receivable from hospital business were RMB12.5 million ($1.9 million),representing an 19.4% decrease] from accounts receivable of RMB15.5 million as of December 31,2020. The number of Days Sales Outstanding was 76 days in the first half of 2021.

As of June 30,the Company had bank loans and other borrowings totaling RMB2.2 billion ($338.8 million).

Recent Developments

The Guangzhou Hospital commenced operation in June 2021. The Guangzhou Hospital is situated in Sino-Singapore Guangzhou Knowledge City (the "Knowledge City"),Guangzhou'snewest modern development district. The Guangzhou Hospital provides high-quality diagnostic imaging and treatment services,such as radiology,ultrasound and nuclear medicine,diagnosis and remote consultation,education and training,to all the medical institutions,premium clinics and medical institutions around the Knowledge City. Advanced imaging diagnostic equipment,such as CT,magnetic resonance,and PET-CT,have been installed in the Guangzhou Hospital. The Guangzhou Hospital will equip with the leading-edge image-guided ProBeam proton therapy system by Varian.

The Company's internet hospital obtained the licence in April 2021 and commenced operation in May 2021. The internet hospital aims to provide a series of cancer care services,on the Company's online platforms. Integrating the Company's newly established internet hospital with its conventional network business,the Company has developed Cloud System Solutions business that aims to provide comprehensive services for its patients and hospital clients.

Notes:

[1] This announcement contains translations of certain RMB amounts into U.S. dollars at specified rates solely for the convenience of the reader. Unless otherwise noted,all translations of RMB into U.S. dollars are made at a rate of RMB6.4566 to $1.00,the noon buying rate in New York City for cable transfers payable in RMB,as certified for customs purposes by the Federal Reserve Bank of New York on June 30,2021.

[2] The Company adjusts for the accretion of mezzanine equity in the calculation of loss attributable to ordinary shareholders of the Company used in the loss per share for Class A and Class B ordinary shares calculation.

[3] Adjusted EBITDA is defined as net income plus interest,taxes,depreciation,and amortization,share-based compensation expenses,and other adjustments. Other adjustments include foreign exchange gain (loss),net,loss on disposal of long-lived equipment,income from disposal of associate companies,and other income.

About Concord Medical

Concord Medical Services Holdings Limited is a healthcare provider specializing in cancer care,research and prevention. The Company operates a network of medically advanced comprehensive cancer hospitals and standalone radiotherapy and diagnostic imaging centres in China. The Company focuses on providing multidisciplinary cancer care approach in all areas of oncology services in its cancer hospitals. The Company also equips its hospitals with technologically advanced equipment such as the state-of-the-art proton therapy system in its cancer hospitals in Beijing,Shanghai and Guangzhou. As of June 30,the Company operated a network of 24centers based in 18hospitals,spanning over 18cities across 12provinces and administrative regions in China. To ensure the commitment to the highest level of clinical care for patients,the Company offers ongoing education and training for doctors and other medical professionals in its network hospitals and centres in both local and overseas medical institutions. For more information,please see http://ir.ccm.cn.

Safe Harbor Statement

This announcement contains forward-looking statements. These forward-looking statements can be identified by words or phrases such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates" and similar expressions. Forward-looking statements are inherently subject to uncertainties and contingencies beyond the Company's control and based upon premises with respect to future business decisions,which are subject to change. A number of important factors could cause actual results to differ materially from those contained in any forward-looking statement. The Company does not undertake any obligation to update any forward-looking statement,except as required under applicable law.

About Non-GAAP Financial Measures

To supplement the consolidated financial statements presented in accordance with United States Generally Accepted Accounting Principles ("GAAP"),Concord Medical uses certain non-GAAP measures. The Company presents certain of its financial information that is adjusted from results based on GAAP to exclude the impact of share-based compensation expense. The Company believes excluding share-based compensation expense from its GAAP financial measures is useful for its management and investors to assess and analyze the Company's core operating results,as such expense is not directly attributable to the underlying performance of the Company's business operations and do not impact its current cash earnings. Concord Medical also believes these non-GAAP measures excluding share-based compensation expense are important in helping investors to understand the Company's current financial performance and future prospects and to compare business trends among different reporting periods on a consistent basis. In addition,Concord Medical also presents the non-GAAP measure of Adjusted EBITDA,which is defined in this announcement as net income plus interest,depreciation and amortization,and share-based compensation expenses and other adjustments. Other adjustments include foreign exchange gain (loss),income from disposal of associate companies and other income. Furthermore,Adjusted EBITDA eliminates the impact of items that the Company does not consider to be indicative of the performance of the network business and hospital business. The Company believes investors will similarly use Adjusted EBITDA as one of the key metrics to evaluate its financial performance and to compare its current operating results with corresponding historical periods and with other companies in the healthcare services industry. The presentation of these additional measures should not be considered a substitute for or superior to GAAP results or as being comparable to results reported or forecasted by other companies. The non-GAAP measures have been reconciled to GAAP measures in the attached financial information.

Concord Medical Services Holdings Co.,Ltd.

Consolidated Balance Sheets

(in thousands)

December 31,

2020

June 30,2021

RMB

RMB

US$

(Audited)

(Unaudited)

(Unaudited)

ASSETS

Current assets

Cash and cash equivalents

334,264

246,650

38,201

Restricted cash,current portion

4,661

2,228

345

Accounts receivable

77,375

86,183

13,348

Prepayments and other current assets

213,043

223,455

34,609

Inventories

21,610

40,773

6,315

Net investments in direct financing leases,current portion

25,045

3,551

550

Total current assets

675,998

602,840

93,368

Non-current assets

Restricted cash,non-current portion

107,470

27,554

4,268

Property,plant and equipment,net

2,559,191

2,977,352

461,135

Right-of-use assets,net

639,967

632,171

97,911

Net investment in direct financing leases,non-current portion

13,720

6,207

961

Goodwill

213,656

498,312

77,179

Intangible assets,net

522,821

666,311

103,198

Deposits for non-current assets

247,837

233,149

36,110

Long-term investments

313,020

301,388

46,679

Other non-current assets

7,138

7,342

1,137

Prepayment for long term investment

33,720

91,259

14,134

Total non-current assets

4,658,540

5,441,045

842,712

Total assets

5,334,538

6,043,885

936,080

LIABILITIES AND EQUITY

Current liabilities

Accounts payable

18,632

7,954

1,232

Accrued expenses and other liabilities

330,090

418,585

64,831

Income tax payable

858

834

129

Operating lease liabilities,current

13,661

19,181

2,971

Short-term bank and other borrowings

24,481

-

-

Long-term bank and other borrowings,current portion

124,395

106,998

16,572

Total current liabilities

512,117

553,552

85,735

Non-current liabilities

Long-term bank and other borrowings,non-current portion

1,968,048

2,080,586

322,242

Deferred tax liabilities

153,339

169,719

26,286

Operating lease liabilities,non-current

223,478

220,155

34,098

Other long-term liabilities

76,726

76,726

11,884

Total non-current liabilities

2,421,591

2,547,186

394,510

Total liabilities

2,933,708

3,100,738

480,245

Contingently redeemable noncontrolling interests

2,913,675

3,412,889

528,589

EQUITY

Class A ordinary shares

68

68

10

Class B ordinary shares

37

37

6

Treasury stock

(8)

(7)

(1)

Additional paid-in capital

1,840,026

1,872,953

290,083

Accumulated other comprehensive loss

(46,429)

(40,194)

(6,225)

Accumulated deficit

(2,456,649)

(2,788,050)

(431,814)

Total Concord Medical Services Holdings Limited shareholders' deficit

(662,955)

(955,193)

(147,941)

Noncontrolling interests

150,110

485,451

75,187

Total deficit

(512,845)

(469,742)

(72,754)

Total liabilities,mezzanine equity and deficit

5,080

Concord Medical Services Holdings Co.,Ltd.

Consolidated Profit & Loss

(in thousands,except for number of shares and per share data)

June 30,2020

June 30,2021

RMB

RMB

US$

(Unaudited)

(Unaudited)

(Unaudited)

Revenues,net of business tax,value-added tax and related surcharges

Network

37,674

128,737

19,939

Hospital

45,337

64,150

9,936

Total net revenues

83,011

192,887

29,875

Cost of revenues:

Network

(14,644)

(95,652)

(14,815)

Hospital

(71,839)

(94,855)

(14,691)

Total cost of revenues

(86,483)

(190,507)

(29,506)

Gross (loss) / profit

(3,472)

2,380

369

Operating expenses:

Selling expenses

(22,095)

(13,665)

(2,116)

General and administrative expenses

(134,397)

(172,623)

(26,736)

Operating loss

(159,964)

(183,908)

(28,483)

Interest expense

(20,835)

(25,906)

(4,012)

Foreign exchange (loss) gain,net

(1,736)

18,489

2,864

(Loss) Income on disposal of long-lived equipment

(5)

-

-

Interest income (expense)

4,050

2551

395

Income from equity method investments

1,252

9,088

1,408

Other income (expense),net

4,958

2,662

412

Gain on disposal of an equity method investment

8,151

-

-

Loss before income tax

(164,129)

(177,024)

(27,416)

Income tax (expenses) benefit

(1,833)

5,331

826

Net loss

(165,962)

(171,693)

(26,590)

Net loss attributable to noncontrolling interests

(37,167)

(81,363)

(12,602)

Net loss attributable to Concord Medical Services Holdings Limited

(128,795)

(90,330)

(13,988)

Loss per share for Class A and Class B ordinary shares

Basic

(2.23)

(2.53)

(0.39)

Diluted

(2.23)

(2.53)

(0.39)

Weighted average number of class A and class B ordinary shares

outstanding:

Basic

130,241,995

131,053,858

131,858

Diluted

130,858

Other comprehensive loss,net of tax of nil

Foreign currency translation,net tax of nil

(6,867)

6,234

966

Total other comprehensive loss,net of tax

(6,234

966

Comprehensive loss

(172,829)

(165,459)

(25,624)

Comprehensive loss attributable to noncontrolling interests

(37,602)

Comprehensive loss attributable to Concord Medical Services Holdings

Limited's shareholders

(135,662)

(84,096)

(13,022)

Reconciliations of non-GAAP results of operations measures to the

nearest comparable GAAP measures (*)

(in RMB thousands,except per share data unaudited)

For the six months ended

For the six months ended

June 30,2021

Non-

Non-

GAAP

GAAP

GAAP

GAAP

Measure

Adjustment

Measure

Measure

Adjustment

Measure

Operating loss

(159,964)

10,916

(149,048)

(183,908)

8,647

(175,261)

Net loss

(165,962)

10,916

(155,046)

(171,693)

8,647

(163,046)

Basic loss per share for Class A and

Class B ordinary shares

(2.23)

0.08

(2.15)

(2.53)

0.07

(2.46)

Diluted loss per share for Class A and

Class B ordinary shares

(2.23)

0.08

(2.15)

(2.53)

0.07

(2.46)

(*) The only adjustment is share-based

compensation.

Reconciliation from net income to adjusted EBITDA(*) (in RMB

thousands,unaudited)

For the six months ended

For the six months ended

June 30,2021

Net loss

(165,693)

Interest expenses,net

16,785

23,355

Income tax expenses / benefit

1,833

(5,331)

Depreciation and amortization

34,715

38,476

Share-based compensation

10,916

8,647

Other adjustments

(11,368)

(21,151)

Adjusted EBITDA

(113,081)

(127,697)

EBITDA margin

-136%

-66%

(*) Definition of adjusted EBITDA: Adjusted EBITDA is defined as net loss plus interest expenses,income tax expenses

(benefit),share-based compensation expenses and other adjustments. Other adjustments include

foreign exchange gain(loss),gain on disposal of an equity method investment and

other income,net.

View original content:https://www.prnewswire.com/news-releases/concord-medical-reports-financial-results-for-the-first-half-of-2021-301442101.html